Selank comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-01. Numbers and descriptions here follow the published literature rather than marketing material.
Pharmacokinetic data are limited. Like most short peptides, Selank is vulnerable to plasma and tissue peptidases, and its measured half-life in circulation is short, on a minutes scale. The Pro-Gly-Pro tail slows this degradation but does not eliminate it. Intranasal administration is the route described in most reports, with absorption through the nasal mucosa and a hypothesized path into the central nervous system that avoids the blood-brain barrier. Direct measurements of human brain exposure are unavailable, so distribution claims rest on inference from animal work.
Clinical evidence comes mainly from small studies conducted in Russia, several of which were open-label or lacked robust blinding. Reported outcomes include lower anxiety scores, changes in attention measures, and effects on asthenic states following illness. Sample sizes are typically in the tens of participants, and independent replication outside the region is scarce. Reviews published in English generally note the limited methodological quality of the underlying trials. Whether the compound produces clinically meaningful effects under rigorous conditions remains unresolved.
Proposed mechanisms center on modulation of the GABA system, but no single molecular target has been confirmed. Rodent studies report changes in GABA-A receptor expression and in the turnover of serotonin, dopamine, and norepinephrine in several brain regions. Increases in brain-derived neurotrophic factor and its receptor have also been described after repeated administration. These findings come largely from animal models, and the degree to which they describe human neurochemistry remains an open question. The mechanism is best characterized as multi-system and not fully resolved.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
| Property | Value | Notes |
|---|---|---|
| Route studied | Intranasal | Predominant route in published reports |
| Circulation stability | Short, minutes scale | Peptidases cleave it; the tail slows the process |
| Analytical method | RP-HPLC with mass spectrometry | Used for identity and purity assessment |
| Reported outcome domains | Anxiety and cognitive measures | Derived from small, mostly regional trials |
| Regulatory status | Marketed in Russia | Availability outside that market is limited |
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
A nitrogen atom has seven electrons. In the ground state, they are arranged in the electron configuration 1s22s22p1x2p1y2p1z. It, therefore, has five valence electrons in the 2s and 2p orbitals, three of which (the p-electrons) are unpaired. It has one of the highest electronegativities among the elements (3.04 on the Pauling scale), exceeded only by chlorine (3.16), oxygen (3.44), and fluorine (3.98). (The light noble gases, helium, neon, and argon, would presumably also be more electronegative, and in fact are on the Allen scale.) Following periodic trends, its single-bond covalent radius of 71 pm is smaller than those of boron (84 pm) and carbon (76 pm), while it is larger than those of oxygen (66 pm) and fluorine (57 pm). The nitride anion, N3−, is much larger at 146 pm, similar to that of the oxide (O2−: 140 pm) and fluoride (F−: 133 pm) anions. The first three ionisation energies of nitrogen are 1.402, 2.856, and 4.577 MJ·mol−1, and the sum of the fourth and fifth is 16.920 MJ·mol−1. Due to these very high figures, nitrogen has no simple cationic chemistry. The lack of radial nodes in the 2p subshell is directly responsible for many of the anomalous properties of the first row of the p-block, especially in nitrogen, oxygen, and fluorine. The 2p subshell is very small and has a very similar radius to the 2s shell, facilitating orbital hybridisation. It also results in very large electrostatic forces of attraction between the nucleus and the valence electrons in the 2s and 2p shells, resulting in very high electronegativities.
The first President of Cuba, Tomás Estrada Palma, was a Freemason. After his election in April 1902, he returned from exile to Cuba and went on a tour of the island's Masonic Lodges. On May 20, 1902, the Cuban flag was raised for the first time on its own, without the American Flag flying next to it. The next day, on May 21, General Máximo Gómez placed that same exact flag in a wooden chest and handed the chest to Grand Master José Fernández Pellón Castellanos, to ceremonially honor the sacrifices that Cuban Freemasons had made, and the efforts that Cuban Freemasonry had contributed to the creation of an independent Cuba. Freemasonry steadily grew across Cuba. New Masonic Temples were erected across the island, and a Masonic Band was created. Freemasons largely returned to the normal work of charity; schools were built, shoes were dispensed to children in need, an ambulance was given to a hospital, hurricane relief funds were gathered for Puerto Rico and other islands, medical procedures were funded, and a dental dispensary was created. Four entirely English-speaking Lodges were established in communities that had been established by American colonists to the island; Island Lodge in Havana, Landmark Lodge in Camagüey, Kane Lodge in Banes, and Santa Fe Lodge on the Isle of Pines. By 1953, there were 400 English-speaking members across these English language Lodges.
In the Ubaid in the 5th millennium BC, blades were manufactured from obsidian extracted from outcrops located in modern-day Turkey. Ancient Egyptians used obsidian imported from the eastern Mediterranean and southern Red Sea regions. Obsidian scalpels older than 2100 BC have been found in a Bronze Age settlement in Turkey. In the eastern Mediterranean area the material was used to make tools, mirrors and decorative objects. The use of obsidian tools was present in Japan near areas of volcanic activity. Obsidian was mined during the Jōmon period. Obsidian has also been found in Gilat, a site in the western Negev in Israel. Eight obsidian artifacts dating to the Chalcolithic Age found at this site were traced to obsidian sources in Anatolia. Neutron activation analysis (NAA) on the obsidian found at this site helped to reveal trade routes and exchange networks previously unknown.
Sources: en.wikipedia.org
The reaction is reversible as well, allowing cellular ATP levels to be maintained during anoxic conditions. This process in animals is seen to be coupled with metabolic suppression to allow certain fish, such as goldfish, to survive environmental anoxic conditions for a short period.
The SAS raiding force, headed by Lieutenant-Colonel David Stirling, was discovered by an Italian reconnaissance unit, prompting Stirling to turn back to Kufra. The Rhodesians, meanwhile, were led into impassable country by a local guide, and swiftly retreated after being attacked by German bombers. Southern Rhodesian pilots played a part in the siege of Malta during 1942. John Plagis, a Rhodesian airman of Greek ancestry, joined the multinational group of Allied airmen defending the strategically important island in late March and on 1 April achieved four aerial victories in an afternoon, thereby becoming the siege's first Spitfire flying ace. By the time of his withdrawal in July he had been awarded the Distinguished Flying Cross twice. The British finally delivered vital supplies to Malta on 15 August with Operation Pedestal. Back in Salisbury, the Southern Rhodesian government was coming under pressure from Britain to put its armed forces under the purview of a regional command. Huggins decided in late October 1942 to join a unified Southern African Command headed by South Africa's Jan Smuts. This choice was motivated by a combination of strategic concerns and geopolitical manoeuvring. Apart from considering South Africa a more appropriate partner in geographical, logistical and cultural terms, Huggins feared that the alternative—joining the British East Africa Command—might detract from the autonomous nature of Southern Rhodesia's war effort, with possible constitutional implications. A shift in the deployment of the colony's troops duly occurred.
== Ethics == Ethical issues with bioarchaeology revolve around the treatment and respect for the dead. Large-scale skeletal collections were first amassed in the US in the 19th century, largely the remains of Native Americans. No permission was granted by surviving family for study and display. Federal laws such as 1990's NAGPRA (Native American Graves Protection and Repatriation Act) allowed Native Americans to regain control over their ancestors' remains and associated artifacts. Many archaeologists did not realize that many people perceive archaeologists as non-productive and/or grave robbers. Concerns about mistreatment of remains are not unfounded: in a 1971 Minnesota excavation, White and Native American remains were treated differently; Whites were reburied, while Native Americans were moved to a natural history museum. African American bioarchaeology grew after NAGPRA and its effect of ending the study of Native American remains. Bioarchaeology in Europe was not as disrupted by repatriation issues. However, because much of European archaeology has been focused on classical roots, artifacts and art have been emphasized and Roman and post-Roman skeletal remains were nearly completely neglected until the 1980s. In prehistoric European archaeology, biological remains began to be analyzed earlier than in classical archaeology.
The adoption came a year after the same body rejected the renewal of the mandate for the Group of Eminent Experts (GEE), which the organization describes as an international, impartial, and independent body established by the Human Rights Council in 2017 that reported on rights violations and abuses in Yemen.
Sources: en.wikipedia.org
Reports describe effects on GABA-A receptor expression, monoamine turnover, and neurotrophic factor levels. These are proposed mechanisms drawn mainly from animal models. No single molecular target has been established.
Intranasal delivery is the route described in most published work. It is used because the peptide is degraded quickly once it reaches circulation. Direct evidence of brain penetration in humans is lacking.
Most trials are small, regionally concentrated, and often lack rigorous blinding or placebo control. Independent replication is limited. Reviews in English generally rate the evidence as preliminary.
Intranasal administration predominates in both animal and human research because it avoids hepatic first-pass metabolism. Injectable and intraperitoneal routes appear in animal work mainly for comparison.